Blog

The commencement of 2026 has heralded a definitive paradigmatic shift in the trajectory of consumer health technology, characterised principally by the transition from passive information retrieval to active, agentic health management. At the vanguard of this transformation is OpenAI’s aggressive expansion into the healthcare vertical, a strategy crystallised by two simultaneous, high-impact manoeuvres : the acquisition of the specialised healthcare technology startup Torch Health and the launch of the dedicated ChatGPT Health environment. On January 12, 2026, OpenAI confirmed the acquisition of Torch Health in an all-equity transaction valued between $60 Million and $100 Million. This strategic consolidation represents more than a mere talent acquisition; it signals the integration of critical infrastructure designed to solve the "context problem" in medical artificial intelligence. For nearly a decade, the promise of AI in healthcare has been stymied by the fragmentation of patient data, longitudinal records scattered across disparate electronic health record (EHR) systems, pdf lab reports, and siloed wearable metrics. The industry's inability to synthesise this fragmented data into a coherent "medical memory" has prevented Large Language Models (LLMs) from moving beyond generic medical advice to personalised health surveillance. &nbsp;&nbsp; Simultaneously, the deployment of ChatGPT Health, a privacy-segregated ecosystem within OpenAI's flagship platform, and OpenAI for Healthcare, a HIPAA-compliant enterprise suite, marks the operationalisation of this new capability. By integrating Torch’s "context engine," OpenAI aims to transition its 40 million daily health-seeking users from receiving static answers to engaging with a "personal super-assistant" capable of longitudinal reasoning. &nbsp;&nbsp; This report provides an analysis of this pivotal moment in health technology. It scrutinises the architectural necessity of Torch’s "medical memory," dissects the complex failure of the Forward Health model that spawned the Torch team and evaluates the intensifying competitive landscape involving Anthropic and legacy health IT incumbents.&nbsp; Full Report: <a href="https://www.healthcare.digital/single-post/openai-s-acquisition-of-torch-health-and-the-future-of-chatgpt-health">https://www.healthcare.digital/single-post/openai-s-acquisition-of-torch-health-and-the-future-of-chatgpt-health</a>Furthermore, it examines the privacy paradox introduced by the consumerisation of sensitive medical records outside the protective umbrella of HIPAA, forecasting the clinical and ethical ripple effects of this technological convergence.

The Future of ChatGPT Health

Anthropic has just launched Claude for Healthcare, a HIPAA‑ready offering aimed at providers, payers, life sciences, and consumer health applications, with a focus on safety, interoperability, and complex workflow automation. For an M&amp;A / build‑vs‑partner view, it effectively positions Claude as an “agentic copilot” across admin ops, clinical documentation, and life‑sciences workflows, and is already embedded in several scaled health players.​What Claude for Healthcare is Anthropic now offers a dedicated Claude for Healthcare stack, including configuration and resources so providers, payers, and health apps can use Claude through HIPAA‑ready products.​ The launch coincides with expanded life‑sciences tooling (e.g., connectors into scientific platforms, trial ops, regulatory workflows) under the broader Claude for Life Sciences umbrella.​ Core healthcare use cases Provider / health system side​Prior authorisation and claims: Drafting and packaging prior auth requests and appeals by pulling from records, coverage policies, and guidelines. Patient communication and triage: Sorting portal messages, flagging urgent issues, and drafting responses or routing tasks to the right team. Clinical documentation: Used by partners like Commure for ambient scribing and documentation, targeting “millions of clinician hours” saved annually.​ Payer and revenue‑cycle side​Claims appeals and utilization review: Assembling evidence from EMR, guidelines, and policies to support denials/appeals. Member communication: Explaining coverage decisions and benefits in plain language and assisting with care navigation. Life sciences and pharma applications Claude is being used by large pharma and biotech (e.g., Sanofi, AstraZeneca, Genmab) for literature review, protocol drafting, regulatory document prep, and analytics.​ Example: A Phase II Parkinson’s trial protocol was generated in about an hour instead of days, using Claude to structure and iterate on the design.​ With integrations like Benchling, Claude can draft SOPs, study protocols, consent forms, and support GxP‑compliant documentation and submissions.​ Patient‑facing and data interoperability angle A new consumer‑health push lets patients link their electronic health records (EHRs) via partners like HealthEx, then ask Claude questions about their own data (history summaries, test result explanations, pattern detection across devices, etc.).​ Anthropic has joined the U.S. CMS “Health Tech Ecosystem” pledge, positioning Claude as an interoperability layer to break data silos and support AI assistants that can navigate health data across systems.​ Technical performance and safety positioning Claude’s latest flagship (Opus 4.x) is benchmarked as strong on clinical knowledge, with reported performance at around 95% on the 2025 MRCGP exam, above mean human GP scores, underscoring its viability for complex clinical reasoning support (though not as an autonomous clinician).​ Anthropic is explicitly marketing safety as a differentiator in regulated environments, emphasising constrained use, auditable outputs, and alignment work to reduce harmful or hallucinated clinical guidance.<a href="https://claude.com/solutions/healthcare">https://claude.com/solutions/healthcare</a>

Anthropic launches Claude for Healthcare

Distressed M&amp;A is forecast to be a structural, not cyclical, feature of European HealthTech and MedTech dealmaking in 2026, driven by a convergence of regulatory capital requirements, funding market resets and operational pressures that create a clearing event for undercapitalised assets.​To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener" data-mce-selected="inline-boundary">lloyd@nelsonadvisors.co.uk</a>Core drivers of distressed activityRegulatory Darwinism is the primary catalyst. Full MDR/IVDR implementation, EUDAMED mandatory go‑live (May 2026), and AI Act compliance have created capital‑intensive barriers that act as a “guillotine” for stand‑alone SMEs. Notified Body certification, clinical data generation, post‑market surveillance and data governance requirements are largely untenable for companies without deep balance sheets, forcing them into the arms of larger strategics that possess scaled regulatory infrastructure. This is explicitly framed as “compliance‑driven M&amp;A,” where acquirers target IP, customer bases and regulatory approvals from firms that cannot afford the transition costs.​Private equity liquidity pressures compound the dynamic. With ~$2.5 trillion in global dry powder and a significant backlog of 2019–2021 vintage assets requiring exit, PE sponsors face immense pressure to return capital to LPs. However, the IPO market remains selective, focusing only on assets with proven profitability and scale. Consequently, sponsors are increasingly utilising continuation funds, secondary buyouts and forced sales to drive consolidation, with 38% of European M&amp;A respondents expecting distress‑driven deals to dominate buy‑side activity. Financing difficulties and valuation gaps are cited as key deal drivers, creating a pool of forced sellers.​Operational and market stress is accelerating in specific sub‑sectors. Companies that achieved product‑market fit but failed to secure reimbursement traction or scale revenue are now facing flat or shrinking growth, making them prime targets for IP‑only or acqui‑hire transactions at compressed valuations. The combination of elevated cost of capital, investor retrenchment and regulatory overhead is creating a “funding reset” that will flush out “zombie” assets through down rounds, recapitalisations and pay‑to‑play restructurings.​Most vulnerable sub‑sectorsMedTech devices and diagnostics face the clearest distress risk. MDR/IVDR transition costs, UKCA divergence and rising quality‑system expenses (QMSR alignment, EUDAMED, sustainability rules) are squeezing smaller UK and EU manufacturers, many of which are expected to sell under pressure. Generalist CDMOs are also vulnerable, though specialists in viral vectors, ADCs and sterile injectables remain attractive.​Digital health and HealthTech platforms that built inflated cap tables during 2021–22 but lack clear reimbursement or sustainable unit economics are prime distressed targets. Investors are prioritising companies with robust clinical validation and AI integration; those without face acquisition for IP rather than revenue. Early‑stage AI companies that “moved fast and broke things” without regulatory foundations are becoming uninvestable and will exit as distressed sales.​Veterinary, dental and ophthalmology services in the UK are experiencing a “corporatisation clash” and “locum crisis,” with regulatory scrutiny (the “CMA Effect”) pushing capital toward Continental Europe where corporate ownership is lower (15–20% vs. ~60% in the UK). This is creating distressed sellers in the UK and fragmented buy‑and‑build opportunities in Southern Europe.​Buyer strategies and opportunities Strategic acquirers (Roche, Siemens Healthineers, Abbott, Medtronic, J&amp;J, Philips) are using M&amp;A to secure “compliance moats” and data sovereignty. They are targeting AI‑native platforms, robotics and digital pathology assets that can be integrated across existing portfolios, with a focus on H1 2026 to get ahead of EHDS implementation.​Private equity is deploying buy‑and‑build strategies in fragmented services (veterinary, dental, fertility) across Southern and Eastern Europe, acquiring at low multiples (6x–8x EBITDA) and integrating into pan‑European platforms that command premium exits (12x–15x EBITDA). PE is also forming club deals with corporate buyers in high‑growth verticals like mental health tech, femtech and preventive care.​US corporate venture funds are increasingly active in Europe, seeking early exposure to robotics and AI innovation before valuations reach US levels, effectively bridging the “Series B Gap” for European companies.​Deal structure and valuation implications Distressed transactions are expected to feature:Compressed valuations relative to 2021–22 peaks, with multiples stabilising around ~4.8x revenue and low‑teens EV/EBITDA by Q4 2025.​ IP‑only or acqui‑hire structures for digital health assets lacking revenue scale.​ Regulatory due diligence as a core financial assessment, with compliance profiles treated as assets or liabilities.​ Continuation funds and secondary buyouts to manage PE portfolio churn.​ Outlook 2026 is described as the year European HealthTech “grows up,” graduating from the “laboratory” phase to the “factory” phase. The winners will not be those with the most disruptive technology, but those with the strongest compliance moats, interoperable data and industrial logic. Distressed M&amp;A is the primary mechanism clearing the market of subscale, over‑funded or non‑compliant assets, making it a central pillar of European HealthTech and MedTech consolidation rather than a peripheral trend.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Distressed M&A predicted to play a major role in European HealthTech and MedTech 2026

European HealthTech this week is dominated by EU‑level AI and data policy moving into implementation, new EU and national funding windows for digital health, and early‑year signals of tighter but more predictable MedTech regulation in 2026. Dealmaking and startup activity continue to tilt towards AI‑enabled automation, data‑rich diagnostics and devices, and cross‑border virtual care infrastructure.​Policy and regulatory moves The European Commission has released a new report on emerging health technologies, feeding into implementation of the AI Act, MDR/IVDR and broader digital health strategy as the reference framework for “robust and trustworthy” AI in care.​ EU commentary now explicitly links the AI Act, MDR and the Digital Omnibus as the core stack for health AI, aiming to harmonise rules and cut compliance friction for innovators from 2026 onward.​ NHS England is preparing for 2026 workforce and digital policy changes, with an overhaul of workforce models tied to expanded use of digital tools and automation across the system.Funding windows and capital flowsThe UNITE Open Call for European digital health innovators is live with a €4 million budget, offering up to €1 million per cross‑border project and a submission deadline of 15 January 2026.​The 2026 cycle of the Future of Health Grant in Switzerland is opening this month, targeting early‑stage digital health startups in telemedicine, patient analytics, preventive care and digital therapeutics.​ Horizon Europe’s 2026–2027 work programme allocates part of a €14 billion R&amp;I envelope to health and digital technologies, while Global Health EDCTP3 plans up to €147 million across six research topics relevant to infectious‑disease‑linked digital and clinical innovation.​ MedTech regulation and market structure New guidance and draft implementing regulations around MDR/IVDR and Notified Body conformity assessments are progressing, with consultation timelines running into mid‑January and pointing to tighter but more predictable oversight for EU devices and IVDs.​ EUDAMED’s staged roll‑out, with four modules now functional, starts a six‑month transition that will increase transparency on device registrations, vigilance and market actors from mid‑2026, directly affecting payer scrutiny and MedTech due diligence.​ Market outlook pieces frame 2026 as a “Great Rationalisation” year in European HealthTech/MedTech, with PE‑backed roll‑ups in services and strategic consolidation in AI radiology, digital pathology and tech‑enabled home care, alongside portfolio pruning under MDR/IVDR.​ Startups, AI automation and CES health tech A feature on European startups highlights strong investor interest in AI tools that automate healthcare administration and back‑office workflows, especially those integrating with hospital information systems rather than purely consumer apps.​ Health tech launches at CES 2026 include novel consumer‑adjacent devices such as smart menstrual pads, allergy devices and LED‑based masks, underscoring ongoing convergence between consumer wellness and regulated HealthTech.​ Eindhoven‑based ShanX Medtech secured a €24 million round to accelerate ultra‑rapid diagnostics against antimicrobial resistance, reinforcing the region’s position as a MedTech innovation hub.​ Key implications for deals EU‑backed grants and Horizon Europe calls are providing non‑dilutive capital for cross‑border platforms built around EHDS‑style data flows, which may emerge as future roll‑up nuclei in digital health infrastructure.​ The combination of AI‑focused regulation, EUDAMED transparency and MDR/IVDR simplification is expected to concentrate M&amp;A on fewer, higher‑value assets with clear regulatory narratives and data advantages, particularly in robotics, neuro, advanced diagnostics and AI‑enhanced workflows.&gt;&gt;&gt;European MedTech this week is being shaped by tightening but clearer EU regulation (MDR/IVDR plus EUDAMED timing), notable funding rounds in cardiology and anti‑microbial resistance, and continued investor focus on robotics, neuro and data‑rich devices.​Regulation and guidance The European Commission’s late‑2025 proposal to simplify MDR/IVDR is setting the 2026 agenda, focusing on digitalised procedures, harmonised Notified Body practice and clearer rules for software, AI and nano‑materials.​ EUDAMED has been confirmed as fully mandatory from 28 May 2026, with four modules (actor registration, UDI/device registration, notified bodies &amp; certificates, market surveillance) triggering fixed deadlines and making transparency, traceability and post‑market oversight central to EU MedTech.​ MDCG‑endorsed documents from December 2025 are adding detailed guidance on MDR/IVDR application to software and AI‑driven products, which many MedTech software and SaMD vendors are now using to plan 2026 submissions.​ Market structure and MDR pressure2026 is framed as a defining MDR year, with looming transition deadlines (2027–2028) and Notified Body bottlenecks forcing portfolio rationalisation and prioritisation of higher‑value devices.​ EUDAMED’s go‑live in May 2026 means all devices must be registered in the database before being placed on the EU market, adding operational burden but also standardising data for payers and regulators.​ Strategy and law‑firm notes expect M&amp;A to concentrate on fewer, higher‑quality assets that combine clean MDR roadmaps, strong clinical and economic evidence, and clear health‑technology‑assessment narratives.​ Funding rounds and capital flows French MedTech FineHeart has secured about €83 million in a mix of private capital and non‑dilutive European public funding to advance its implantable device for advanced heart failure, underlining investor appetite for high‑acuity cardiovascular hardware‑plus‑data plays.​ Dutch, female‑led ShanX Medtech has raised €24 million to accelerate ultra‑rapid diagnostics against antimicrobial resistance, reinforcing AMR diagnostics as a key EU strategic priority.​ Weekly funding wraps list ShanX and FineHeart among the top European startup deals for 5–9 January 2026, signalling a strong start to the year for MedTech fundraising.​ Innovation focus: robotics, neuro and data Coverage of Paris‑based Robeauté’s microrobotics platform for diagnosing, treating and monitoring brain disease highlights the tilt toward complex neuro and micro‑robotic interventions as a 2026 MedTech theme.​ Outlook pieces emphasise devices that pair novel hardware with rich data exhaust and AI‑enhanced workflows, especially in cardiovascular, neurovascular, advanced diagnostics and surgical robotics.​ Analysts expect European investors to favour platforms that can integrate with EHDS‑style data infrastructures, creating defensible positions around longitudinal data and decision‑support rather than “device‑only” propositions.​ Key implications for strategy and deals Regulatory clarity around MDR/IVDR and EUDAMED is raising the bar on quality systems and data, increasing the relative value of assets with scalable compliance infrastructure and experienced regulatory teams.​ Portfolio pruning under MDR/IVDR, combined with capital flowing into high‑complexity segments like heart failure, AMR diagnostics and neuro‑robotics, is likely to create a two‑speed market: consolidation among premium, evidence‑rich platforms and potential distress among subscale, non‑differentiated device players.To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

This Week in European HealthTech and MedTech: 9th January 2026

The most interesting health tech trends at CES 2026 cluster around AI‑driven “longevity” tools, more medical‑grade wearables, women’s health, and increasingly clinical home diagnostics and robotics. Many of these products sit very close to regulated care, with obvious implications for payers, providers, and acquirers.​1. Longevity and cardiometabolic insights at home Smart scales like Withings Body Scan 2 now track up to ~60 metrics including ECG, arterial stiffness, metabolic efficiency and hypertension risk, reframing the bathroom scale as a cardiometabolic risk screen.​ “Longevity mirrors” such as NuraLogix’s Longevity Mirror analyse facial blood‑flow patterns via AI to estimate physiological age, metabolic and heart health in under a minute.​ 2. AI everywhere in consumer health AI is moving from gimmick to core infrastructure, powering skin diagnostic systems, nutrition analysis, therapy booths and portable scanning devices rather than standalone “AI gadgets.”​ Many products now pair sensors with cloud AI to generate automated, personalised coaching or risk flags (e.g., Samsung Brain Health for cognitive decline, Garmin nutrition and health‑status scoring).​ 3. Next‑gen wearables and continuous remote monitoring Major brands and new entrants are extending wearables from step‑counts to continuous monitoring of HRV, sleep, respiration and early deviation from personal baselines, positioning devices as remote‑monitoring endpoints.​ CES programming explicitly highlights AI‑driven precision medicine and telehealth, with exhibitors such as Abbott, ResMed, Oura, Ultrahuman, Vivoo and Withings anchoring an expanded Digital Health Summit.​ 4. Women’s health and hormonal analytics A “smart menstrual pad” from Vivoo measures follicle‑stimulating hormone on‑pad to track fertility, hormonal health and potential infections, pushing lab‑like testing into routine products.​ Dedicated digital health content on women’s health at CES 2026 spans pelvic support, bone strength and menopause‑oriented solutions, reflecting fast‑maturing FemTech as a mainstream category.​ 5. Mental health, neuro and cognitive tech Therapy booths and AI‑guided mental health tools are emerging as a distinct vertical, with focus on scalable, behaviour‑change‑oriented interventions rather than simple meditation apps.​ Samsung’s Brain Health concept analyses gait, voice and sleep patterns from Galaxy wearables to flag early signs of cognitive decline, hinting at future dementia‑screening pipelines into neurology.​ 6. Exoskeletons and rehabilitation robotics Walking exoskeletons such as Ascentiz H1 Pro show lighter, modular designs for longer‑distance assistance, signalling progress toward everyday mobility aids rather than lab‑only devices.​ Cosmo Robotics’ Bambini Kids, an overground paediatric exoskeleton with powered ankles for ages ~2.5–7, targets gait training in conditions like cerebral palsy and has already won a CES Innovation Award.​ 7. Ambient and smart‑home health platforms Samsung’s CES 2026 demos frame the home as a “care companion,” integrating sensors, cameras and AI to monitor safety events, health signals and family wellbeing through existing consumer infrastructure.​ Broader CES health content emphasises using smart home, sleep and environmental monitoring to support ageing‑in‑place and “human sustainability,” blurring consumer IoT and care delivery.​ 8. At‑table and point‑of‑life diagnostics Allergen Alert’s portable “mini‑lab” detects common allergens in food to restore confidence for people with severe allergies, with expansion to more allergens planned.​ Similar point‑of‑life diagnostics at CES include fertility and hormone sensing in menstrual products and urine‑based tests tied into smartphone apps, shifting diagnostics to daily contexts.​ 9. Personalised recovery, massage and musculoskeletal support RheoFit A1, an AI‑powered robotic roller that auto‑maps the body and delivers a 10‑minute adaptive massage, illustrates a wave of recovery robotics aimed at office workers and athletes.​ CES sessions on prevention, early detection and behaviour change frame MSK, posture and rehabilitation solutions as cost‑saving levers for payers, not just wellness gadgets.​ 10. Data‑hungry ecosystems and GLP‑1‑adjacent wellness Commentary around CES 2026 highlights a fast‑growing “GLP‑1 ecosystem,” with devices, apps and services designed to support weight‑loss, nutrition, and lifestyle changes around metabolic drugs.​ Across categories, vendors are betting that consumers will trade deep behavioural, biometric and environmental data in exchange for actionable, longitudinal health guidance, making data governance a critical differentiator.

The 10 Most Interesting Health Technology Trends at CES 2026

The year 2026 marks the definitive conclusion of FemTech’s infancy, a period characterised by "pink" wellness apps and direct-to-consumer hygiene products and its transition into a mature, industrialised sector of the global healthcare economy.&nbsp;The convergence of regulatory enforcement, artificial intelligence integration, and institutional capital has fundamentally altered the trajectory of the market. What was once considered a niche vertical comprising menstrual trackers and fertility aids has expanded into a comprehensive "female health infrastructure" that underpins the economic and clinical stability of global health systems.&nbsp;By 2026, the global market for FemTech is valued at approximately USD $59.51 Billion, serving as a critical waypoint on a trajectory toward USD $246 Billion by 2035.This report offers an exhaustive analysis of the FemTech landscape in 2026. It argues that the sector is defined by three structural shifts. First, the move from reactive symptom logging to proactive, biomarker-driven diagnostics, utilising novel mediums such as menstrual blood and continuous nervous system monitoring.&nbsp;Second, the bifurcation of the global regulatory landscape, where the European Union’s AI Act imposes strict compliance moats while the United States’ FDA TEMPO pilot incentivises rapid real-world evidence generation.&nbsp;Third, the transformation of investment theses from speculative venture bets on user acquisition to strategic infrastructure plays focused on longitudinal outcomes, evidenced by the multi-billion dollar valuations of platforms like Maven Clinic and the massive philanthropic interventions of the Gates Foundation.The narrative of 2026 is one of integration. Women’s health is no longer isolated in the OB-GYN clinic; it is embedded in corporate benefit packages, prioritized in national health strategies in the UK and UAE, and encoded into the algorithms of general medical AI. This report dissects these dynamics, offering a granular view of the technological, financial, and geopolitical forces shaping the future of female health.To read the full report click here &gt; <a href="https://www.healthcare.digital/single-post/femtech-predictions-and-trends-2026">https://www.healthcare.digital/single-post/femtech-predictions-and-trends-2026</a>To discuss how Nelson Advisors can help your HealthTech, MedTech, Health AI or Digital Health company, please email <a data-mce-href="mailto:lloyd@nelsonadvisors.co.uk" href="mailto:lloyd@nelsonadvisors.co.uk" title="lloyd@nelsonadvisors.co.uk" target="_blank" rel="noopener">lloyd@nelsonadvisors.co.uk</a>

Nelson Advisors

Blog

The Future of ChatGPT Health

Anthropic launches Claude for Healthcare

Distressed M&A predicted to play a major role in European...

This Week in European HealthTech and MedTech: 9th January...

The 10 Most Interesting Health Technology Trends at CES 2026

Nelson Advisors FemTech Predictions and Trends 2026